Sherif Zaki worked at the Centers for Disease Control and Prevention for more than 30 years, and was renowned for uncovering crucial intel on various outbreak-causing scourges, from Ebola and Zika to SARS and influenza.
The Scientist’s Creative Services Team | 1 min read
Angela Rasmussen and Ya-Chi Ho explore the positive and negative aspects of the host immune response to SARS-CoV-2 infection and discuss how this knowledge influences therapeutic benefits.
The recent news of consumers hoarding gasoline in the face of a brief closure of one of the world’s biggest petroleum pipelines is just the latest episode of panic buying since the COVID-19 pandemic started.
In addition to continued scruitiny of the SARS-CoV-2 virus, research on similar pathogens could aid in the fight against the COVID-19 pandemic and future disease outbreaks.
Half a year after infection, people who had recovered from COVID-19 had robust antibodies, along with traces of the virus in their gut, which may drive long-lasting immunity.
Researchers turn to familiar model animals, along with some fresh strategies, to develop countermeasures against SARS-CoV-2 and investigate the biology of infection.